



Annual General Meeting

May 2024

IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR)

WWW.IMRICOR.COM

Disclaimer

The material contained in this presentation is intended to be general background information on Imricor Medical Systems, Inc. (**Imricor**) and its activities.

The information is supplied in summary form and is therefore not necessarily complete. It is not intended that it be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs. The material contained in this presentation may include information derived from publicly available sources that have not been independently verified. None of Imricor, its officers, directors, employees and agents, nor any other person makes any representation or warranty as to the accuracy, completeness or reliability of the information contained in this presentation and none of them accepts responsibility or liability for any errors or omissions in this presentation whatsoever.

Unless otherwise noted, financial information in this presentation has been prepared in accordance with accounting principles generally accepted in the U.S. (**US GAAP**) and are denominated in US dollars.

This presentation may contain statements that constitute “forward-looking statements”. Forward-looking statements are statements about matters that are not historical facts. Forward-looking statements appear in a number of places in this presentation and include statements regarding Imricor’s intent, belief or current expectations with respect to its business and operations, market conditions, results of operations and financial condition.

Imricor uses words such as ‘will’, ‘may’, ‘expect’, ‘intend’, ‘seek’, ‘would’, ‘should’, ‘could’, ‘continue’, ‘plan’, ‘estimate’, ‘anticipate’, ‘believe’, ‘probability’, ‘risk’, ‘aim’, or other similar words to identify forward-looking statements. These forward-looking statements reflect Imricor’s current views with respect to future events and are subject to change, certain risks, uncertainties and assumptions which are, in many instances, beyond its control, and have been made based upon management’s expectations and beliefs concerning future developments and their potential effect upon Imricor. There can be no assurance that future developments will be in accordance with Imricor’s expectations or that the effect of future developments on Imricor will be those anticipated. Actual results could differ materially from

those which we expect, depending on the outcome of various factors. Investors and others are cautioned not to place undue reliance on forward-looking statements, particularly in light of the current economic climate and significant volatility, uncertainty and disruption caused by the COVID-19 pandemic.

Imricor is under no obligation to update any forward-looking statements contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation.

Imricor’s CHES Depositary Interests (**CDIs**) are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933, as amended, and in accordance with the procedures established pursuant to the provisions of a no-action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no-action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this presentation.

The distribution of this document outside of Australia may be restricted by law and any such restrictions should be observed. This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or in any other jurisdiction.



Imricor's Board of Directors and CFO



Steve Wedan
Executive Chair,
President, & CEO

Mark Tibbles
Deputy Chair,
Non-Executive Director

Anita Messal
Non-Executive Director

Peter McGregor
Non-Executive Director

Jonathon Gut
CFO



Chair's Address

A photograph of two medical professionals in a blue-tinted iCMR (interventional cardiac magnetic resonance) suite. They are wearing blue scrubs, masks, and hairnets. One is wearing large headphones. They are positioned around a patient lying on a table inside a large circular gantry. To the right, there are several large monitors displaying medical data and images. The overall scene is dimly lit with a strong blue color cast.

"What may have taken several hours in the x-ray lab took less than an hour to perform using NorthStar in the iCMR."

Dr. Marco Götte - Amsterdam UMC, April 2024

Priorities for 2024

Clinical Trials

- Execute VISABL-AFL global trial to support FDA approval in the US
- Execute VISABL-VT trial to support expanded indications for ablation catheter in Europe

Commercial Momentum

- Consistent procedure volume at active sites
- Steady activation of new sites
- Build sales pipeline across Europe, Middle East, and (pending TGA) Australia/New Zealand



Imricor Leadership Team

Management



Steve Wedan
President and Chief Executive Officer, and Board Chair



Jonathon Gut
Vice President of Finance and Chief Financial Officer



Gregg Stenzel
Chief Operating Officer



Jennifer Weisz
Vice President of Regulatory and Quality



Nick Twohy
Vice President of Marketing and Business Development



Dan Sunnarborg
Vice President of R&D



Vic Fabano
Vice President of Operations



Nick Corkill
Vice President Corporate Strategy



Kate Lindborg
Senior Director of Clinical Affairs



Greg Englehardt
Senior Director of Sales

Board of Directors



Steve Wedan
President and Chief Executive Officer, and Board Chair



Mark Tibbles
Deputy Chair and Lead Independent Director



Peter McGregor
Non-executive Director



Anita Messal
Non-executive Director



Contact Information

Investors & Australian Media:

Simon Hinsley
NWR Communications
simon@nwrcommunications.com.au
+61 401 809 653

Investors:

Steve Wedan
Executive Chair, President & CEO
steve.wedan@imricor.com

Nick Corkill
Vice President, Corporate Strategy
Nick.corkill@imricor.com
+61 450 475 633

Rest of World Media:

Nick Twohy
Vice President, Marketing and Business Development
nick.twohy@imricor.com



imricor

FOLLOW US

